1
|
Chan CW, Lin BF. Folate Deficiency Enhanced Inflammation and Exacerbated Renal Fibrosis in High-Fat High-Fructose Diet-Fed Mice. Nutrients 2023; 15:3616. [PMID: 37630806 PMCID: PMC10458828 DOI: 10.3390/nu15163616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 08/15/2023] [Accepted: 08/16/2023] [Indexed: 08/27/2023] Open
Abstract
The prevalence of obesity and chronic kidney disease (CKD) is increasing simultaneously and rapidly worldwide. Our previous study showed that folate deficiency increased lipid accumulation and leptin production of adipocytes. Whether folate plays a role in CKD, particularly obesity-related nephropathy remains unclear. To investigate the effects of folate deficiency on CKD in diet-induced obese mice, four groups of male C57BL/6 mice were fed either a normal-fat diet (NF) with folate (NF+f); NF without folate (NF-f); high-fat high-fructose diet (HFF) with folate (HFF+f); or HFF without folate (HFF-f) for 12 months during the study. The results showed that HFF increased not only body weight, fasting blood glucose, total cholesterol (TC), low-density lipoprotein (LDL)-cholesterol, and blood pressure, but also cytokines levels, such as interleukin (IL)-2, interferon (IFN)-γ, IL-17A/F, IL-6, monocyte chemoattractant protein (MCP)-1, and transforming growth factor (TGF)-β1. The indicators of kidney failure including urinary protein, neutrophil gelatinase-associated lipocalin (NGAL), renal type I and IV collagen deposits and leptin content, and serum creatinine were also increased by HFF. Folate-deficient diets further elevated serum TC, LDL-cholesterol, IL-6, tumor necrosis factor (TNF)-α, MCP-1, TGF-β1, and leptin, but decreased IL-10 level, and thus exacerbated renal fibrosis. To investigate the possible mechanisms of folate deficiency on renal injury, phosphorylation of pro-fibrosis signaling molecules, including signal transducer and activator of transcription (STAT)3 and small mothers against decapentaplegic (Smad)2/3, were assayed. Both HFF and folate deficiency significantly increased the phosphorylation of STAT3 and Smad2/3, suggesting synergistic effects of HFF-f on chronic renal inflammation and fibrosis. In conclusion, the results demonstrated that folate deficiency might aggravate inflammatory status and enhance renal fibrosis.
Collapse
Affiliation(s)
| | - Bi-Fong Lin
- Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei 10617, Taiwan;
| |
Collapse
|
2
|
Abstract
The prevalence of obesity has increased dramatically during the past decades, which has been a major health problem. Since 1975, the number of people with obesity worldwide has nearly tripled. An increasing number of studies find obesity as a driver of chronic kidney disease (CKD) progression, and the mechanisms are complex and include hemodynamic changes, inflammation, oxidative stress, and activation of the renin-angiotensin-aldosterone system (RAAS). Obesity-related kidney disease is characterized by glomerulomegaly, which is often accompanied by localized and segmental glomerulosclerosis lesions. In these patients, the early symptoms are atypical, with microproteinuria being the main clinical manifestation and nephrotic syndrome being rare. Weight loss and RAAS blockers have a protective effect on obesity-related CKD, but even so, a significant proportion of patients eventually progress to end-stage renal disease despite treatment. Thus, it is critical to comprehend the mechanisms underlying obesity-related CKD to create new tactics for slowing or stopping disease progression. In this review, we summarize current knowledge on the mechanisms of obesity-related kidney disease, its pathological changes, and future perspectives on its treatment.
Collapse
Affiliation(s)
- Zongmiao Jiang
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China
| | - Yao Wang
- Department of Orthopedics, The Second Hospital Jilin University, Changchun, China
| | - Xue Zhao
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China
| | - Haiying Cui
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China
| | - Mingyue Han
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China
| | - Xinhua Ren
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China
| | - Xiaokun Gang
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China
| | - Guixia Wang
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China
| |
Collapse
|
3
|
Wang L, Gao T, Li Y, Xie Y, Zeng S, Tai C, Feng Y, Shen P, Wang B. A long-term anti-inflammation markedly alleviated high-fat diet-induced obesity by repeated administrations of overexpressing IL10 human umbilical cord-derived mesenchymal stromal cells. Stem Cell Res Ther 2022; 13:259. [PMID: 35715850 PMCID: PMC9204983 DOI: 10.1186/s13287-022-02935-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 03/12/2022] [Indexed: 12/23/2022] Open
Abstract
Objectives Obesity is a chronic process and could activate various inflammatory responses, which in turn aggravates obesity and related metabolic syndrome. Here we explored whether long-term inhibition of inflammation could successfully alleviate high-fat diet (HFD)-induced obesity. Methods We constructed stable overexpressing interleukin 10 (IL10) human umbilical cord-derived mesenchymal stromal cells (HUCMSCs) which repeatedly were applied to obesity mice with HFD feeding to obtain a long-term anti-inflammation based on the prominent anti-inflammation effects of IL10 and immunomodulatery effects of HUCMSCs. Then we monitored the features of obesity including body weight, serum ALT, AST, and lipids. In addition, glucose homeostasis was determined by glucose tolerance and insulin sensitivity tests. The infiltrated macrophages in adipose tissues and hepatic lipid accumulation were detected, and the expressions of adipogenesis and inflammatory genes in adipose tissues were examined by real-time (RT) PCR and western blot analysis. Results Compared with HUCMSCs, IL10-HUCMSCs treatment had much better anti-obesity effects including body weight reduction, less hepatic lipids accumulation, lower amount and size of adipocyte, greater glucose tolerance, less systemic insulin resistance, and less adipose tissue inflammation in HFD feeding mice. Finally, IL10-HUCMSCs could decrease the activation of MAPK JNK of adipose tissue induced by HFD. The inhibition of MAPK JNK signal pathway by a small chemical molecule SP600125 in 3T3-L1 cells, a preadipocyte line, reduced the differentiation of adipocytes and lipid droplet accumulation. Conclusion A lasting anti-inflammation based on gene modified stem cell therapy is an effective strategy in preventing diet-induced obesity and obesity-related metabolic syndrome.
Collapse
Affiliation(s)
- Liudi Wang
- Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210000, China
| | - Tianyun Gao
- Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210000, China
| | - Yu Li
- State Key Laboratory of Pharmaceutical Biotechnology and the Comprehensive Cancer Center, School of Life Science, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing University, Nanjing, Jiangsu Province, China
| | - Yuanyuan Xie
- Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210000, China
| | - Sheng Zeng
- Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210000, China
| | - Chenxu Tai
- Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210000, China
| | - Yirui Feng
- State Key Laboratory of Pharmaceutical Biotechnology and the Comprehensive Cancer Center, School of Life Science, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing University, Nanjing, Jiangsu Province, China
| | - Pingping Shen
- State Key Laboratory of Pharmaceutical Biotechnology and the Comprehensive Cancer Center, School of Life Science, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing University, Nanjing, Jiangsu Province, China.
| | - Bin Wang
- Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210000, China. .,College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.
| |
Collapse
|
4
|
Subramanian N, Tavira B, Hofwimmer K, Gutsmann B, Massier L, Abildgaard J, Juul A, Rydén M, Arner P, Laurencikiene J. Sex-specific regulation of IL-10 production in human adipose tissue in obesity. Front Endocrinol (Lausanne) 2022; 13:996954. [PMID: 36313784 PMCID: PMC9606404 DOI: 10.3389/fendo.2022.996954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Accepted: 09/20/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Obesity-associated metabolic complications display sexual dimorphism and can be impacted by cytokines. We previously showed that interleukin-10 (IL-10) was upregulated in white adipose tissue (WAT) of obese women with type 2 diabetes (T2D). Whether this pertains to men is unknown. The aim of this study was to compare the impact of obesity and T2D on WAT IL-10 levels in men versus women. METHODS Plasma and subcutaneous WAT biopsies were obtained from 108 metabolically well-characterized individuals. WAT IL10 expression/secretion and WAT-resident IL-10-secreting macrophage number were measured. Circulating sex hormone levels were correlated to WAT IL10 expression in 22 individuals and sex hormone effects on macrophage IL10 expression were investigated in vitro. RESULTS Obese women with T2D showed increased IL10 expression/secretion and IL-10-secreting WAT macrophage number compared to other female groups. This difference was absent in men. Non-obese women and men with T2D showed similar IL-10 levels compared to healthy controls, indicating that T2D alone does not regulate IL-10. Although WAT IL10 expression correlated with serum estrone (E1) concentrations, recombinant E1 did not affect macrophage IL10 expression in vitro. CONCLUSION WAT IL-10 levels are higher in women with obesity and T2D, but not in men and this effect is primarily attributed to obesity per se. This is less likely to be driven by circulating sex hormones. We propose that the WAT IL-10 might exert protective effects in obesity-associated chronic inflammation in women which could be one of the contributing factors for the decreased morbidity observed in women during obesity than men.
Collapse
Affiliation(s)
- Narmadha Subramanian
- Lipid laboratory, Unit of Endocrinology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
- *Correspondence: Narmadha Subramanian, ; Jurga Laurencikiene,
| | - Beatriz Tavira
- Lipid laboratory, Unit of Endocrinology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Kaisa Hofwimmer
- Lipid laboratory, Unit of Endocrinology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Beate Gutsmann
- Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
| | - Lucas Massier
- Lipid laboratory, Unit of Endocrinology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
- Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany
| | - Julie Abildgaard
- Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- Danish Diabetes Academy, Odense University Hospital, Odense, Denmark
| | - Anders Juul
- Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Mikael Rydén
- Lipid laboratory, Unit of Endocrinology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Peter Arner
- Lipid laboratory, Unit of Endocrinology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Jurga Laurencikiene
- Lipid laboratory, Unit of Endocrinology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
- *Correspondence: Narmadha Subramanian, ; Jurga Laurencikiene,
| |
Collapse
|
5
|
Abstract
Introduction: NAFLD is often under-diagnosed, even though rates of its co-morbidities such as obesity and type2 diabetes mellitus, prominent statuses of inflammation, are significantly high. The spleen-liver axis is gaining much credit in the last years like other well-known organ axes.Areas covered: PubMed/MEDLINE was searched for relevant articles related to concomitant occurrence of NAFLD and spleen. Areas covered in this review include: (1) updated findings of spleen dimensions at ultrasonography, (2) discussion of current data on pathophysiological connections between obesity-related NAFLD and increased volume of the spleen, and (3) analysis of current immune-mediated mechanisms characterizing the so.called chronic low-grade inflammation leading to insulin resistance.Expert opinion: The advances in explaining mechanisms underlying the spleen involvement in immune regulation, coupled with research about the role of spleen in NAFLD, could impact real world outcomes through establishing better tools for a precocious diagnosis. Using both liver and spleen ultrasonography, technique largely dealt with in this review, could expand the possibility to cover an adequate diagnostic path toward NAFLD, reaching a good sensibility and specificity.
Collapse
Affiliation(s)
- Giovanni Tarantino
- Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Naples, Italy
| | - Vincenzo Citro
- Department of General Medicine, "Umberto I" Hospital, Nocera Inferiore (SA), Nocera Inferiore, Italy
| | - Clara Balsano
- Department of Clinical Medicine, Life, Health & Environmental Sciences-MESVA, University of L'Aquila, L'Aquila, Italy
| |
Collapse
|
6
|
Steen EH, Wang X, Balaji S, Butte MJ, Bollyky PL, Keswani SG. The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Adv Wound Care (New Rochelle) 2020; 9:184-198. [PMID: 32117582 PMCID: PMC7047112 DOI: 10.1089/wound.2019.1032] [Citation(s) in RCA: 186] [Impact Index Per Article: 46.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 06/18/2019] [Indexed: 02/06/2023] Open
Abstract
Significance: Fibrosis is the endpoint of chronic disease in multiple organs, including the skin, heart, lungs, intestine, liver, and kidneys. Pathologic accumulation of fibrotic tissue results in a loss of structural integrity and function, with resultant increases in morbidity and mortality. Understanding the pathways governing fibrosis and identifying therapeutic targets within those pathways is necessary to develop novel antifibrotic therapies for fibrotic disease. Recent Advances: Given the connection between inflammation and fibrogenesis, Interleukin-10 (IL-10) has been a focus of potential antifibrotic therapies because of its well-known role as an anti-inflammatory mediator. Despite the apparent dissimilarity of diseases associated with fibrotic progression, pathways involving IL-10 appear to be a conserved molecular theme. More recently, many groups have worked to develop novel delivery tools for recombinant IL-10, such as hydrogels, and cell-based therapies, such as ex vivo activated macrophages, to directly or indirectly modulate IL-10 signaling. Critical Issues: Some efforts in this area, however, have been stymied by IL-10's pleiotropic and sometimes conflicting effects. A deeper, contextual understanding of IL-10 signaling and its interaction with effector cells, particularly immune cells, will be critical to future studies in the field. Future Directions: IL-10 is clearly a gatekeeper of fibrotic/antifibrotic signaling. The development of novel therapeutics and cell-based therapies that capitalize on targets within the IL-10 signaling pathway could have far-reaching implications for patients suffering from the consequences of organ fibrosis.
Collapse
Affiliation(s)
- Emily H. Steen
- Department of Surgery, Baylor College of Medicine, Houston, Texas
- Laboratory for Regenerative Tissue Repair, Texas Children's Hospital, Houston, Texas
| | - Xinyi Wang
- Laboratory for Regenerative Tissue Repair, Texas Children's Hospital, Houston, Texas
| | - Swathi Balaji
- Laboratory for Regenerative Tissue Repair, Texas Children's Hospital, Houston, Texas
| | - Manish J. Butte
- Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics, University of California, Los Angeles, Los Angeles, California
| | - Paul L. Bollyky
- Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine, Stanford, California
| | - Sundeep G. Keswani
- Department of Surgery, Baylor College of Medicine, Houston, Texas
- Laboratory for Regenerative Tissue Repair, Texas Children's Hospital, Houston, Texas
- Division of Pediatric Surgery, Department of Surgery, Texas Children's Hospital, Houston, Texas
| |
Collapse
|
7
|
Ishida T, Iizuka M, Ou Y, Morisawa S, Hirata A, Yagi Y, Jobu K, Morita Y, Miyamura M. Juzentaihoto Suppresses Muscle Atrophy in Streptozotocin-Induced Diabetic Mice. Biol Pharm Bull 2019; 42:1128-1133. [PMID: 31257289 DOI: 10.1248/bpb.b18-00983] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In diabetic patients, skeletal muscle atrophy occurs due to increased oxidative stress and inflammation. Skeletal muscle atrophy reduces the QOL of patients and worsens life prognosis. Therefore, development of preventive therapy for muscle atrophy in hyperglycemic state is eagerly awaited. Juzentaihoto is a medicinal herb that has a function to supplement physical strength, and it is expected to prevent muscle atrophy. To determine the preventive effect of juzentaihoto on muscle atrophy in hyperglycemic state, streptozotocin (STZ) was administered to induce diabetes in mice and the preventive effect of juzentaihoto was evaluated. Mice that received juzentaihoto extract (JTT) showed that the decrease in muscle fiber cross-sectional area in the gastrocnemius muscle was reversed. Additionally, the expression level of tumor necrosis factor α (TNF-α), an inflammatory cytokine, in serum decreased, and that of ubiquitin ligase (atrogin-1, muscle RING-finger protein-1) mRNA in skeletal muscle decreased. An anti-inflammatory cytokine interleukin-10 showed increased levels in the serum and increased levels in spleen cell culture supernatant collected from mice that received JTT. JTT had no effect on the blood glucose level. These results suggest that prophylactic administration of JTT to STZ-induced diabetic mice affects immune cells such as in spleen, causing an anti-inflammatory effect and inhibiting excessive activation of the ubiquitin-proteasome system, to reverse muscle atrophy.
Collapse
Affiliation(s)
- Tomoaki Ishida
- Department of Pharmacy, Kochi Medical School Hospital.,Department of Biomedical Science, Kochi Medical Graduate School
| | - Michiro Iizuka
- Department of Biomedical Science, Kochi Medical Graduate School
| | - Yanglan Ou
- Department of Pharmacy, Kochi Medical School Hospital
| | - Shunpei Morisawa
- Department of Pharmacy, Kochi Medical School Hospital.,Department of Biomedical Science, Kochi Medical Graduate School
| | - Ayumu Hirata
- Department of Biomedical Science, Kochi Medical Graduate School
| | - Yusuke Yagi
- Department of Biomedical Science, Kochi Medical Graduate School
| | - Kohei Jobu
- Department of Biomedical Science, Kochi Medical Graduate School
| | - Yasuyo Morita
- Department of Biomedical Science, Kochi Medical Graduate School
| | - Mitsuhiko Miyamura
- Department of Pharmacy, Kochi Medical School Hospital.,Department of Biomedical Science, Kochi Medical Graduate School
| |
Collapse
|
8
|
Buchan L, St Aubin CR, Fisher AL, Hellings A, Castro M, Al-Nakkash L, Broderick TL, Plochocki JH. High-fat, high-sugar diet induces splenomegaly that is ameliorated with exercise and genistein treatment. BMC Res Notes 2018; 11:752. [PMID: 30348225 PMCID: PMC6198361 DOI: 10.1186/s13104-018-3862-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Accepted: 10/17/2018] [Indexed: 01/04/2023] Open
Abstract
Objective We tested the effect of exercise training and genistein treatment on splenomegaly in mice fed a high-fat, high-sugar diet (HFSD). Results Male and female C57BL6 mice fed HFSD containing 60% fat along with drinking water containing 42 g/L sugar (55% sucrose/45% fructose) for 12 weeks exhibited significant obesity, hyperglycemia, and elevated plasma IL-6 levels. This was accompanied by splenomegaly characterized by spleen weights 50% larger than mice fed standard chow (P < 0.05) with enlarged rad and white pulps. Mice fed HFSD and treated with a combination of exercise (30 min/day, 5 days/week) and genistein (600 mg genistein/kg diet) had reduced spleen weight (P < 0.05). The decrease in spleen weight was associated with a significant improvement in red-to-white pulp area ratio and plasma glucose and IL-6 (P < 0.05). Our findings indicate that reversal of splenomegaly by regular exercise and genistein treatment may be important in the clinical management of HFSD-induced obesity.
Collapse
Affiliation(s)
- Levi Buchan
- Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA
| | | | - Amy L Fisher
- College of Graduate Studies, Midwestern University, Glendale, AZ, USA
| | - Austin Hellings
- Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA
| | - Monica Castro
- Department of Anatomy, College of Graduate Studies and Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA
| | - Layla Al-Nakkash
- Department of Physiology, College of Graduate Studies and Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA
| | - Tom L Broderick
- Department of Physiology, Laboratory of Diabetes and Exercise Metabolism, College of Graduate Studies and Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA
| | - Jeffrey H Plochocki
- Department of Anatomy, College of Graduate Studies and Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA. .,Department of Medical Education, College of Medicine, University of Central Florida, 6850 Lake Nona Blvd, Orlando, FL, 85308, USA.
| |
Collapse
|
9
|
Ruggiero SA, Huber JS, Murrant CL, Brunt KR, Simpson JA. Splenic blood-flow response following myocardial infarction in rat. Can J Physiol Pharmacol 2018; 96:1060-1068. [PMID: 30102865 DOI: 10.1139/cjpp-2018-0134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
During physiological stress (e.g., exercise, hypoxia), blood flow is shunted to specific anatomical regions to protect critical organs; yet, splenic blood flow in these circumstances remains to be investigated. Despite being classically viewed as a non-critical organ, recent experimental and epidemiological evidence suggests the spleen plays a significant role in cardiovascular pathophysiology. We hypothesized that splenic blood flow is prioritized in the development of heart failure (i.e., chronic state of reduced cardiac output). Five-week-old male Wistar rats were randomized for either myocardial infarction (MI; n = 58) or sham (n = 56) surgery. At 2, 5, and 9 weeks post-surgery, Doppler ultrasound measurements of the splenic, left renal, left common carotid, and left femoral arteries were performed. Cardiac function was assessed at all time points using echocardiography and at 9 weeks post-surgery using invasive hemodynamic analysis. Splenic and cerebral blood flow was preferentially maintained at 9 weeks post-MI, whereas blood flow to the lower limb and kidney were reduced. Spleen size increased by 5 weeks post-MI and remained elevated. Splenic blood flow was maintained in conditions of decreased cardiac output, when other tissues showed decreased blood flow. The maintenance of blood flow in the face of decreased cardiac output indicates that splenic function is being prioritized during heart failure.
Collapse
Affiliation(s)
- Sara A Ruggiero
- a Department of Human Health and Nutritional Science, College of Biological Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada
| | - Jason S Huber
- a Department of Human Health and Nutritional Science, College of Biological Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.,b IMPART team Canada Investigator Network
| | - Coral L Murrant
- a Department of Human Health and Nutritional Science, College of Biological Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada
| | - Keith R Brunt
- b IMPART team Canada Investigator Network.,c Department of Pharmacology, Dalhousie Medicine New Brunswick, Dalhousie University, Saint John, NB E2K 5E2, Canada
| | - Jeremy A Simpson
- a Department of Human Health and Nutritional Science, College of Biological Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.,b IMPART team Canada Investigator Network
| |
Collapse
|
10
|
Kondo H, Kira S, Oniki T, Gotoh K, Fukui A, Abe I, Ikebe Y, Kawano K, Saito S, Aoki K, Okada N, Nagano Y, Akioka H, Shinohara T, Akiyoshi K, Masaki T, Teshima Y, Yufu K, Nakagawa M, Takahashi N. Interleukin-10 treatment attenuates sinus node dysfunction caused by streptozotocin-induced hyperglycaemia in mice. Cardiovasc Res 2018; 115:57-70. [DOI: 10.1093/cvr/cvy162] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 06/20/2018] [Indexed: 12/23/2022] Open
Affiliation(s)
- Hidekazu Kondo
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Shintaro Kira
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Takahiro Oniki
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Koro Gotoh
- Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Oita University, Facultyof Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Akira Fukui
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Ichitaro Abe
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Yuki Ikebe
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Kyoko Kawano
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Shotaro Saito
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Kohei Aoki
- Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Oita University, Facultyof Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Norihiro Okada
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Yasuko Nagano
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Hidefumi Akioka
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Tetsuji Shinohara
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Kumiko Akiyoshi
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Takayuki Masaki
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Yasushi Teshima
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Kunio Yufu
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Mikiko Nakagawa
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| | - Naohiko Takahashi
- Department of Cardiology and Clinical Examination, Oita University, Faculty of Medicine, 1-1 Idaigaoka, Hasama, Oita, Japan
| |
Collapse
|
11
|
Kondo H, Abe I, Gotoh K, Fukui A, Takanari H, Ishii Y, Ikebe Y, Kira S, Oniki T, Saito S, Aoki K, Tanino T, Mitarai K, Kawano K, Miyoshi M, Fujinami M, Yoshimura S, Ayabe R, Okada N, Nagano Y, Akioka H, Shinohara T, Akiyoshi K, Masaki T, Teshima Y, Yufu K, Nakagawa M, Takahashi N. Interleukin 10 Treatment Ameliorates High-Fat Diet–Induced Inflammatory Atrial Remodeling and Fibrillation. Circ Arrhythm Electrophysiol 2018; 11:e006040. [DOI: 10.1161/circep.117.006040] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 03/20/2018] [Indexed: 12/19/2022]
Affiliation(s)
- Hidekazu Kondo
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Ichitaro Abe
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Koro Gotoh
- and Department of Endocrinology, Metabolism, Rheumatology and Nephrology (K.G., K.A., T.M.)
| | - Akira Fukui
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Hiroki Takanari
- Oita University Faculty of Medicine, Japan. Clinical Research Center for Diabetes, Tokushima University Hospital, Japan (H.T.)
| | - Yumi Ishii
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Yuki Ikebe
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Shintaro Kira
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Takahiro Oniki
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Shotaro Saito
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Kohei Aoki
- and Department of Endocrinology, Metabolism, Rheumatology and Nephrology (K.G., K.A., T.M.)
| | - Tomomi Tanino
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Kazuki Mitarai
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Kyoko Kawano
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Miho Miyoshi
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Mami Fujinami
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Seiichiro Yoshimura
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Reika Ayabe
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Norihiro Okada
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Yasuko Nagano
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Hidefumi Akioka
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Tetsuji Shinohara
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Kumiko Akiyoshi
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Takayuki Masaki
- and Department of Endocrinology, Metabolism, Rheumatology and Nephrology (K.G., K.A., T.M.)
| | - Yasushi Teshima
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Kunio Yufu
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Mikiko Nakagawa
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| | - Naohiko Takahashi
- Department of Cardiology and Clinical Examination (H.K., I.A., A.F., Y.I., S.K., T.O., S.S., T.T., K.M., K.K., M.M., M.F., S.Y., R.A., N.O., Y.N., H.A., T.S., K.A., Y.T., K.Y., M.N., N.T.)
| |
Collapse
|
12
|
Larkin BP, Glastras SJ, Chen H, Pollock CA, Saad S. DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease. FASEB J 2018; 32:5215-5226. [PMID: 29688808 DOI: 10.1096/fj.201800205r] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Chronic kidney disease (CKD) is a global epidemic, and its major risk factors include obesity and type 2 diabetes. Obesity not only promotes metabolic dysregulation and the development of diabetic kidney disease but also may independently lead to CKD by a variety of mechanisms, including endocrine and metabolic dysfunction, inflammation, oxidative stress, altered renal hemodynamics, and lipotoxicity. Deleterious renal effects of obesity can also be transmitted from one generation to the next, and it is increasingly recognized that offspring of obese mothers are predisposed to CKD. Epigenetic modifications are changes that regulate gene expression without altering the DNA sequence. Of these, DNA methylation is the most studied. Epigenetic imprints, particularly DNA methylation, are laid down during critical periods of fetal development, and they may provide a mechanism by which maternal-fetal transmission of chronic disease occurs. Our current review explores the evidence for the role of DNA methylation in the development of CKD, diabetic kidney disease, diabetes, and obesity. DNA methylation has been implicated in renal fibrosis-the final pathophysiologic pathway in the development of end-stage kidney disease-which supports the notion that demethylating agents may play a potential therapeutic role in preventing development and progression of CKD.-Larkin, B. P., Glastras, S. J., Chen, H., Pollock, C. A., Saad, S. DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease.
Collapse
Affiliation(s)
- Benjamin P Larkin
- Renal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia
| | - Sarah J Glastras
- Renal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.,Department of Diabetes, Endocrinology, and Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia; and
| | - Hui Chen
- School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, New South Wales, Australia
| | - Carol A Pollock
- Renal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia
| | - Sonia Saad
- Renal Research Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.,School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, New South Wales, Australia
| |
Collapse
|
13
|
Bellinger DL, Lorton D. Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)? Int J Mol Sci 2018; 19:ijms19041188. [PMID: 29652832 PMCID: PMC5979464 DOI: 10.3390/ijms19041188] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2018] [Revised: 04/05/2018] [Accepted: 04/05/2018] [Indexed: 12/21/2022] Open
Abstract
Immune-Mediated Inflammatory Diseases (IMIDs) is a descriptive term coined for an eclectic group of diseases or conditions that share common inflammatory pathways, and for which there is no definitive etiology. IMIDs affect the elderly most severely, with many older individuals having two or more IMIDs. These diseases include, but are not limited to, type-1 diabetes, obesity, hypertension, chronic pulmonary disease, coronary heart disease, inflammatory bowel disease, and autoimmunity, such as rheumatoid arthritis (RA), Sjőgren's syndrome, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and multiple sclerosis. These diseases are ostensibly unrelated mechanistically, but increase in frequency with age and share chronic systemic inflammation, implicating major roles for the spleen. Chronic systemic and regional inflammation underlies the disease manifestations of IMIDs. Regional inflammation and immune dysfunction promotes targeted end organ tissue damage, whereas systemic inflammation increases morbidity and mortality by affecting multiple organ systems. Chronic inflammation and skewed dysregulated cell-mediated immune responses drive many of these age-related medical disorders. IMIDs are commonly autoimmune-mediated or suspected to be autoimmune diseases. Another shared feature is dysregulation of the autonomic nervous system and hypothalamic pituitary adrenal (HPA) axis. Here, we focus on dysautonomia. In many IMIDs, dysautonomia manifests as an imbalance in activity/reactivity of the sympathetic and parasympathetic divisions of the autonomic nervous system (ANS). These major autonomic pathways are essential for allostasis of the immune system, and regulating inflammatory processes and innate and adaptive immunity. Pathology in ANS is a hallmark and causal feature of all IMIDs. Chronic systemic inflammation comorbid with stress pathway dysregulation implicate neural-immune cross-talk in the etiology and pathophysiology of IMIDs. Using a rodent model of inflammatory arthritis as an IMID model, we report disease-specific maladaptive changes in β₂-adrenergic receptor (AR) signaling from protein kinase A (PKA) to mitogen activated protein kinase (MAPK) pathways in the spleen. Beta₂-AR signal "shutdown" in the spleen and switching from PKA to G-coupled protein receptor kinase (GRK) pathways in lymph node cells drives inflammation and disease advancement. Based on these findings and the existing literature in other IMIDs, we present and discuss relevant literature that support the hypothesis that unresolvable immune stimulation from chronic inflammation leads to a maladaptive disease-inducing and perpetuating sympathetic response in an attempt to maintain allostasis. Since the role of sympathetic dysfunction in IMIDs is best studied in RA and rodent models of RA, this IMID is the primary one used to evaluate data relevant to our hypothesis. Here, we review the relevant literature and discuss sympathetic dysfunction as a significant contributor to the pathophysiology of IMIDs, and then discuss a novel target for treatment. Based on our findings in inflammatory arthritis and our understanding of common inflammatory process that are used by the immune system across all IMIDs, novel strategies to restore SNS homeostasis are expected to provide safe, cost-effective approaches to treat IMIDs, lower comorbidities, and increase longevity.
Collapse
Affiliation(s)
- Denise L Bellinger
- Department of Pathology and Human Anatomy, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
| | - Dianne Lorton
- College of Arts and Sciences, Kent State University, Kent, OH 44304, USA.
| |
Collapse
|
14
|
Fujinami M, Kondo H, Yufu K, Shinohara T, Ishii Y, Teshima Y, Nakagawa M, Takahashi N. Association between the baseline peripheral blood monocyte counts, the size of spleen, and the response to cardiac resynchronization therapy. J Cardiol 2018; 71:299-304. [DOI: 10.1016/j.jjcc.2017.09.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 07/22/2017] [Accepted: 09/05/2017] [Indexed: 10/18/2022]
|
15
|
Banerjee S, Sinha K, Chowdhury S, Sil PC. Unfolding the mechanism of cisplatin induced pathophysiology in spleen and its amelioration by carnosine. Chem Biol Interact 2017; 279:159-170. [PMID: 29191451 DOI: 10.1016/j.cbi.2017.11.019] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Revised: 11/17/2017] [Accepted: 11/26/2017] [Indexed: 12/27/2022]
Abstract
cis-Diamminedichloroplatinum (cisplatin) is an effective chemotherapeutic and is widely used for the treatment of various types of solid tumors. Bio-distribution of cisplatin to other organs due to poor targeting towards only cancer cells constitutes the backbone of cisplatin-induced toxicity. The adverse effect of this drug on spleen is not well characterized so far. Therefore, we have set our goal to explore the mechanism of the cisplatin-induced pathophysiology of the spleen and would also like to evaluate whether carnosine, an endogenous neurotransmitter and antioxidant, can ameliorate this pathophysiological response. We found a dose and time-dependent increase of the pro-inflammatory cytokine, TNF-α, in the spleen tissue of the experimental mice exposed to 10 and 20 mg/kg body weight of cisplatin. The increase in inflammatory cytokine can be attributed to the activation of the transcription factor, NF-ĸB. This also aids in the transcription of other pro-inflammatory cytokines and cellular adhesion molecules. Exposure of animals to cisplatin at both the doses resulted in ROS and NO production leading to oxidative stress. The MAP Kinase pathway, especially JNK activation, was also triggered by cisplatin. Eventually, the persistence of inflammatory response and oxidative stress lead to apoptosis through extrinsic pathway. Carnosine has been found to restore the expression of inflammatory molecules and catalase to normal levels through inhibition of pro-inflammatory cytokines, oxidative stress, NF-ĸB and JNK. Carnosine also protected the splenic cells from apoptosis. Our study elucidated the detailed mechanism of cisplatin-induced spleen toxicity and use of carnosine as a protective agent against this cytotoxic response.
Collapse
Affiliation(s)
- Sharmistha Banerjee
- Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India
| | - Krishnendu Sinha
- Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India
| | - Sayantani Chowdhury
- Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India
| | - Parames C Sil
- Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
| |
Collapse
|
16
|
Toita R, Kawano T, Fujita S, Murata M, Kang JH. Increased hepatic inflammation in a normal-weight mouse after long-term high-fat diet feeding. J Toxicol Pathol 2017; 31:43-47. [PMID: 29479139 PMCID: PMC5820102 DOI: 10.1293/tox.2017-0038] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 08/07/2017] [Indexed: 12/22/2022] Open
Abstract
Among five C57BL/6 mice fed a high-fat diet (HFD) for 12 weeks, one mouse showed a body weight (BW) similar to normal diet (ND)-fed mice. We compared obesity-related parameters of three groups (ND-fed mice, one HFD-fed normal-weight mouse, and HFD-fed overweight mice), including visceral fat weight, serum levels of total cholesterol (TC), glucose, and aminotransferases (AST and ALT), adipocyte size, percentage of crown-like structures, severity of hepatic steatosis, and number of inflammatory foci. Compared to ND-fed mice, the HFD-fed normal-weight mouse exhibited a similar visceral fat weight, similar serum levels of glucose and aminotransferases, and a similar percentage of crown-like structures. On the other hand, the serum TC level, adipocyte size, and hepatic steatosis severity of the HFD-fed normal-weight mouse were intermediate between those of ND-fed mice and HFD-fed overweight mice. Interestingly, the number of hepatic inflammatory foci in the HFD-fed normal-weight mouse was remarkably increased compared with those in HFD-fed overweight mice. These results suggest that having BW or serum ALT levels within normal ranges may not guarantee absence of hepatic inflammation and that the HFD-fed normal-weight mouse can be used as an animal model for the study of liver inflammation, particularly in patients with normal BWs and/or serum ALT values.
Collapse
Affiliation(s)
- Riki Toita
- Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 1-8-31 Midorigaoka, Ikeda, Osaka 563-8577, Japan
| | - Takahito Kawano
- Department of Advanced Medical Initiatives, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - Satoshi Fujita
- Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 1-8-31 Midorigaoka, Ikeda, Osaka 563-8577, Japan
| | - Masaharu Murata
- Department of Advanced Medical Initiatives, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - Jeong-Hun Kang
- Division of Biopharmaceutics and Pharmacokinetics, National Cerebral and Cardiovascular Center Research Institute, 5-7-1, Fujishiro-dai, Suita, Osaka 565-8565, Japan
| |
Collapse
|
17
|
Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice. Biomaterials 2016; 110:81-88. [DOI: 10.1016/j.biomaterials.2016.09.018] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Revised: 09/21/2016] [Accepted: 09/28/2016] [Indexed: 02/06/2023]
|
18
|
Matsumoto K, Xavier S, Chen J, Kida Y, Lipphardt M, Ikeda R, Gevertz A, Caviris M, Hatzopoulos AK, Kalajzic I, Dutton J, Ratliff BB, Zhao H, Darzynkiewicz Z, Rose‐John S, Goligorsky MS. Instructive Role of the Microenvironment in Preventing Renal Fibrosis. Stem Cells Transl Med 2016; 6:992-1005. [PMID: 28297566 PMCID: PMC5442777 DOI: 10.5966/sctm.2016-0095] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Accepted: 08/24/2016] [Indexed: 12/26/2022] Open
Abstract
Accumulation of myofibroblasts is a hallmark of renal fibrosis. A significant proportion of myofibroblasts has been reported to originate via endothelial‐mesenchymal transition. We initially hypothesized that exposing myofibroblasts to the extract of endothelial progenitor cells (EPCs) could reverse this transition. Indeed, in vitro treatment of transforming growth factor‐β1 (TGF‐β1)‐activated fibroblasts with EPC extract prevented expression of α‐smooth muscle actin (α‐SMA); however, it did not enhance expression of endothelial markers. In two distinct models of renal fibrosis—unilateral ureteral obstruction and chronic phase of folic acid‐induced nephropathy—subcapsular injection of EPC extract to the kidney prevented and reversed accumulation of α‐SMA‐positive myofibroblasts and reduced fibrosis. Screening the composition of EPC extract for cytokines revealed that it is enriched in leukemia inhibitory factor (LIF) and vascular endothelial growth factor. Only LIF was capable of reducing fibroblast‐to‐myofibroblast transition of TGF‐β1‐activated fibroblasts. In vivo subcapsular administration of LIF reduced the number of myofibroblasts and improved the density of peritubular capillaries; however, it did not reduce the degree of fibrosis. A receptor‐independent ligand for the gp130/STAT3 pathway, hyper‐interleukin‐6 (hyper‐IL‐6), not only induced a robust downstream increase in pluripotency factors Nanog and c‐Myc but also exhibited a powerful antifibrotic effect. In conclusion, EPC extract prevented and reversed fibroblast‐to‐myofibroblast transition and renal fibrosis. The component of EPC extract, LIF, was capable of preventing development of the contractile phenotype of activated fibroblasts but did not eliminate TGF‐β1‐induced collagen synthesis in cultured fibroblasts and models of renal fibrosis, whereas a receptor‐independent gp130/STAT3 agonist, hyper‐IL‐6, prevented fibrosis. In summary, these studies, through the evolution from EPC extract to LIF and then to hyper‐IL‐6, demonstrate the instructive role of microenvironmental cues and may provide in the future a facile strategy to prevent and reverse renal fibrosis. Stem Cells Translational Medicine2017;6:992–1005
Collapse
Affiliation(s)
- Kei Matsumoto
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
- Showa University, Tokyo, Japan
| | - Sandhya Xavier
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Jun Chen
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Yujiro Kida
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Mark Lipphardt
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Reina Ikeda
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
- Okayama University, Okayama, Japan
| | - Annie Gevertz
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Mario Caviris
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | | | - Ivo Kalajzic
- University of Connecticut Health Center, Farmington, Connecticut, USA
| | - James Dutton
- Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, USA
| | - Brian B. Ratliff
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Hong Zhao
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Zbygniew Darzynkiewicz
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
- Renal Research Institute, New York Medical College, Valhalla, New York, USA
| | - Stefan Rose‐John
- Institute of Biochemistry, Christian‐Albrechts University, Kiel, Germany
| | - Michael S. Goligorsky
- Department of Medicine, New York Medical College, Valhalla, New York, USA
- Department of Pharmacology, New York Medical College, Valhalla, New York, USA
- Department of Physiology, New York Medical College, Valhalla, New York, USA
- Department of Pathology, New York Medical College, Valhalla, New York, USA
| |
Collapse
|
19
|
Aumailley L, Garand C, Dubois MJ, Johnson FB, Marette A, Lebel M. Metabolic and Phenotypic Differences between Mice Producing a Werner Syndrome Helicase Mutant Protein and Wrn Null Mice. PLoS One 2015; 10:e0140292. [PMID: 26447695 PMCID: PMC4598085 DOI: 10.1371/journal.pone.0140292] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 09/23/2015] [Indexed: 12/20/2022] Open
Abstract
Werner syndrome (WS) is a premature aging disorder caused by mutations in a RecQ-family DNA helicase, WRN. Mice lacking part of the helicase domain of the WRN orthologue exhibit many phenotypic features of WS, including metabolic abnormalities and a shorter mean life span. In contrast, mice lacking the entire Wrn protein (i.e. Wrn null mice) do not exhibit a premature aging phenotype. In this study, we used a targeted mass spectrometry-based metabolomic approach to identify serum metabolites that are differentially altered in young Wrn helicase mutant and Wrn null mice. An antibody-based quantification of 43 serum cytokines and markers of cardiovascular disease risk complemented this study. We found that Wrn helicase mutants exhibited elevated and decreased levels, respectively, of the anti-inflammatory cytokine IL-10 and the pro-inflammatory cytokine IL-18. Wrn helicase mutants also exhibited an increase in serum hydroxyproline and plasminogen activator inhibitor-1, markers of extracellular matrix remodeling of the vascular system and inflammation in aging. We also observed an abnormal increase in the ratio of very long chain to short chain lysophosphatidylcholines in the Wrn helicase mutants underlying a peroxisome perturbation in these mice. Remarkably, the Wrn mutant helicase protein was mislocalized to the endoplasmic reticulum and the peroxisomal fractions in liver tissues. Additional analyses with mouse embryonic fibroblasts indicated a severe defect of the autophagy flux in cells derived from Wrn helicase mutants compared to wild type and Wrn null animals. These results indicate that the deleterious effects of the helicase-deficient Wrn protein are mediated by the dysfunction of several cellular organelles.
Collapse
Affiliation(s)
- Lucie Aumailley
- Centre de Recherche du CHU de Québec, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada
| | - Chantal Garand
- Centre de Recherche du CHU de Québec, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada
| | - Marie Julie Dubois
- Quebec Heart and Lung Institute, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada
| | - F. Brad Johnson
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - André Marette
- Quebec Heart and Lung Institute, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada
| | - Michel Lebel
- Centre de Recherche du CHU de Québec, Faculty of Medicine, Laval University, Quebec City, Quebec, Canada
- * E-mail:
| |
Collapse
|
20
|
Stanojević S, Kovačević-Jovanović V, Dimitrijević M, Vujić V, Ćuruvija I, Blagojević V, Leposavić G. Unopposed Estrogen Supplementation/Progesterone Deficiency in Post-Reproductive Age Affects the Secretory Profile of Resident Macrophages in a Tissue-Specific Manner in the Rat. Am J Reprod Immunol 2015; 74:445-56. [PMID: 26307150 DOI: 10.1111/aji.12424] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Accepted: 08/03/2015] [Indexed: 12/27/2022] Open
Abstract
PROBLEM The influence of unopposed estrogen replacement/isolated progesterone deficiency on macrophage production of pro-inflammatory/anti-inflammatory mediators in the post-reproductive age was studied. METHOD OF STUDY Considering that in the rats post-ovariectomy the circulating estradiol, but not progesterone level rises to the values in sham-operated controls, 20-month-old rats ovariectomized at the age of 10 months served as an experimental model. Estrogen and progesterone receptor expression, secretion of pro- and anti-inflammatory cytokines, and arginine metabolism end-products were examined in splenic and peritoneal macrophages under basal conditions and following lipopolysaccharide (LPS) stimulation in vitro. RESULTS Almost all peritoneal and a subset of splenic macrophages expressed the intracellular progesterone receptor. Ovariectomy diminished cytokine production by splenic (IL-1β) and peritoneal (TNF-α, IL-1β, IL-10) macrophages and increased the production of IL-10 by splenic and TGF-β by peritoneal cells under basal conditions. Following LPS stimulation, splenic macrophages from ovariectomized rats produced less TNF-α and more IL-10, whereas peritoneal macrophages produced less IL-1β and TGF-β than the corresponding cells from sham-operated rats. Ovariectomy diminished urea production in both subpopulations of LPS-stimulated macrophages. CONCLUSION Although long-lasting isolated progesterone deficiency in the post-reproductive age differentially affects cytokine production in the macrophages from distinct tissue compartments, in both subpopulations, it impairs the pro-inflammatory/anti-inflammatory cytokine secretory balance.
Collapse
Affiliation(s)
- Stanislava Stanojević
- Immunology Research Centre 'Branislav Janković', Institute of Virology, Vaccines and Sera 'Torlak', Belgrade, Serbia
| | - Vesna Kovačević-Jovanović
- Immunology Research Centre 'Branislav Janković', Institute of Virology, Vaccines and Sera 'Torlak', Belgrade, Serbia
| | - Mirjana Dimitrijević
- Immunology Research Centre 'Branislav Janković', Institute of Virology, Vaccines and Sera 'Torlak', Belgrade, Serbia
| | - Vesna Vujić
- Department of Chemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Ivana Ćuruvija
- Immunology Research Centre 'Branislav Janković', Institute of Virology, Vaccines and Sera 'Torlak', Belgrade, Serbia
| | - Veljko Blagojević
- Immunology Research Centre 'Branislav Janković', Institute of Virology, Vaccines and Sera 'Torlak', Belgrade, Serbia
| | - Gordana Leposavić
- Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| |
Collapse
|
21
|
Kondo H, Takahashi N, Gotoh K, Fukui A, Saito S, Aoki K, Kume O, Shinohara T, Teshima Y, Saikawa T. Splenectomy exacerbates atrial inflammatory fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats: Possible role of spleen-derived interleukin-10. Heart Rhythm 2015; 13:241-50. [PMID: 26144348 DOI: 10.1016/j.hrthm.2015.07.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Indexed: 01/05/2023]
Abstract
BACKGROUND The spleen is important for cardiac remodeling induced by myocardial infarction. However, the role of the spleen in inflammatory atrial fibrosis induced by pressure overload is unknown. OBJECTIVE The purpose of this study was to investigate whether splenectomy (SPX) attenuates or exacerbates pressure overload-induced atrial inflammatory fibrosis and vulnerability to atrial fibrillation (AF) in rats. METHODS Male Sprague-Dawley rats (6 weeks old) were divided into Sham+Sham, Sham+SPX, abdominal aortic constriction (AAC)+Sham, and AAC+SPX groups, and were evaluated for inflammation, fibrosis, and AF on days 2, 4, 14, and 28. RESULTS On day 4, an AAC-induced rise in interleukin-10 (IL-10) level was observed in the spleen, serum, and left atrium (LA), with SPX showing inhibitory effects in the latter 2 instances. In addition, AAC-induced M2 macrophage recruitment into the LA was decreased by SPX, as determined by immunofluorescence labeling (P <.05). On day 28, AAC-induced heterogeneous interstitial fibrosis of the LA was enhanced by SPX (P <.05). Electrophysiologic recordings revealed that the duration of AF and prolongation of interatrial conduction time induced by AAC were increased by SPX (P < .01 and P <.05, respectively). Furthermore, in the AAC+SPX group, the number of macrophages infiltrating into the LA on day 2 was marginal, but increased on day 28 relative to the AAC+Sham group. IL-10 administration attenuated the AAC-induced atrial remodeling that was aggravated by SPX. CONCLUSION The study results suggest that SPX exacerbates AAC-induced inflammatory atrial fibrosis and increases vulnerability to AF after 4 weeks, likely because of depletion of spleen-derived IL-10.
Collapse
Affiliation(s)
- Hidekazu Kondo
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan
| | - Naohiko Takahashi
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan.
| | - Koro Gotoh
- Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Oita University Faculty of Medicine, Oita, Japan
| | - Akira Fukui
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan
| | - Shotaro Saito
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan
| | - Kohei Aoki
- Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Oita University Faculty of Medicine, Oita, Japan
| | - Osamu Kume
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan
| | - Tetsuji Shinohara
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan
| | - Yasushi Teshima
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan
| | - Tetsunori Saikawa
- Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita, Japan
| |
Collapse
|
22
|
Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif 2015; 39:84-92. [PMID: 25662331 DOI: 10.1159/000368940] [Citation(s) in RCA: 361] [Impact Index Per Article: 40.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Despite recent advances in chronic kidney disease (CKD) and end-stage renal disease (ESRD) management, morbidity and mortality in this population remain exceptionally high. Persistent, low-grade inflammation has been recognized as an important component of CKD, playing a unique role in its pathophysiology and being accountable in part for cardiovascular and all-cause mortality, as well as contributing to the development of protein-energy wasting. SUMMARY The variety of factors contribute to chronic inflammatory status in CKD, including increased production and decreased clearance of pro-inflammatory cytokines, oxidative stress and acidosis, chronic and recurrent infections, including those related to dialysis access, altered metabolism of adipose tissue, and intestinal dysbiosis. Inflammation directly correlates with the glomerular filtration rate (GFR) in CKD and culminates in dialysis patients, where extracorporeal factors, such as impurities in dialysis water, microbiological quality of the dialysate, and bioincompatible factors in the dialysis circuit play an additional role. Genetic and epigenetic influences contributing to inflammatory activation in CKD are currently being intensively investigated. A number of interventions have been proposed to target inflammation in CKD, including lifestyle modifications, pharmacological agents, and optimization of dialysis. Importantly, some of these therapies have been recently tested in randomized controlled trials. KEY MESSAGES Chronic inflammation should be regarded as a common comorbid condition in CKD and especially in dialysis patients. A number of interventions have been proven to be safe and effective in well-designed clinical studies. This includes such inexpensive approaches as modification of physical activity and dietary supplementation. Further investigations are needed to evaluate the effects of these interventions on hard outcomes, as well as to better understand the role of inflammation in selected CKD populations (e.g., in children).
Collapse
Affiliation(s)
- Oleh M Akchurin
- Weill Cornell College of Medicine, Department of Pediatrics, New York, N.Y., USA
| | | |
Collapse
|
23
|
|
24
|
Gai Z, Hiller C, Chin SH, Hofstetter L, Stieger B, Konrad D, Kullak-Ublick GA. Uninephrectomy augments the effects of high fat diet induced obesity on gene expression in mouse kidney. Biochim Biophys Acta Mol Basis Dis 2014; 1842:1870-8. [DOI: 10.1016/j.bbadis.2014.07.001] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2014] [Revised: 06/11/2014] [Accepted: 07/01/2014] [Indexed: 11/26/2022]
|
25
|
Börgeson E, Sharma K. Obesity, immunomodulation and chronic kidney disease. Curr Opin Pharmacol 2013; 13:618-24. [PMID: 23751262 DOI: 10.1016/j.coph.2013.05.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2013] [Revised: 05/06/2013] [Accepted: 05/13/2013] [Indexed: 12/20/2022]
Abstract
Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.
Collapse
Affiliation(s)
- Emma Börgeson
- Center for Renal Translational Medicine, Division of Nephrology-Hypertension, Department of Medicine, Institute for Metabolomic Medicine, University of California San Diego, La Jolla, CA, United States
| | | |
Collapse
|
26
|
Araújo N, de Lucena S, Rioja S. Functional Hyposplenism in Long-Standing Renal Transplant Recipients. Transplant Proc 2013; 45:1558-61. [DOI: 10.1016/j.transproceed.2013.01.061] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2012] [Revised: 12/18/2012] [Accepted: 01/15/2013] [Indexed: 10/26/2022]
|
27
|
Whitwell JL, Jack CR, Senjem ML, Parisi JE, Boeve BF, Knopman DS, Dickson DW, Petersen RC, Josephs KA. MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. NEURODEGENER DIS 2009; 6:106-17. [PMID: 19299900 DOI: 10.1159/000209507] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2008] [Accepted: 02/06/2009] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Frontotemporal lobar degeneration (FTLD) can be classified based on the presence of the microtubule-associated protein tau and the TAR DNA binding protein-43 (TDP-43). Future treatments will likely target these proteins, therefore it is important to identify biomarkers to help predict protein biochemistry. OBJECTIVE To determine whether there is an MRI signature pattern of tau or TDP-43 using a large cohort of FTLD subjects and to investigate how patterns of atrophy change according to disease severity using a large autopsy-confirmed cohort of FTLD subjects. METHODS Patterns of gray matter loss were assessed using voxel-based morphometry in 37 tau-positive and 44 TDP-43-positive subjects compared to 35 age and gender-matched controls, and compared to each other. Comparisons were also repeated in behavioral variant frontotemporal dementia (bvFTD) subjects (n = 15 tau-positive and n = 30 TDP-43-positive). Patterns of atrophy were also assessed according to performance on the Clinical Dementia Rating (CDR) scale and Mini-Mental State Examination (MMSE). RESULTS The tau-positive and TDP-43-positive groups showed patterns of frontotemporal gray matter loss compared to controls with no differences observed between the groups, for all subjects and for bvFTD subjects. Patterns of gray matter loss increased in a graded manner by CDR and MMSE with loss in the frontal lobes, insula and hippocampus in mild subjects, spreading to the temporal and parietal cortices and striatum in more advanced disease. CONCLUSION There is no signature pattern of atrophy for tau or TDP-43; however, patterns of atrophy in FTLD progress with measures of clinical disease severity.
Collapse
|